Luke Halpern, Associate Editor

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

A large cohort study found that urate-lowering therapy was associated with a reduction in risk for composite kidney outcomes in patients with stage 3 or higher chronic kidney disease (CKD) and hyperuricemia.

Orforglipron, an oral GLP-1 medication, demonstrated superior weight loss and blood glucose control compared with oral semaglutide in patients with type 2 diabetes (T2D).

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

Laxmi Mehta, MD, discusses widespread patient unawareness of nonstatin cholesterol therapies, common statin misconceptions, and the critical role pharmacists play in bridging the lipid treatment knowledge gap.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.

Oncology pharmacists discuss the transformative role of bispecific antibodies in treating relapsed/refractory multiple myeloma, addressing challenges and patient care strategies.

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

A new cohort study found that proteinuria and lower eGFR—particularly in combination—were prospectively associated with multiple domains of cognitive impairment in patients with chronic kidney disease (CKD).

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.

Sarah Nelson, PharmD, highlights how pharmacists are uniquely positioned to prevent heart disease by identifying cardiovascular risk early, improving medication adherence, and addressing lifestyle and social factors.

TrumpRx offers select branded drugs at cash prices outside insurance, requiring pharmacists to guide patients on cost comparisons, coverage limitations, and safe medication management, according to Ronna Hauser, PharmD.

Anne Cassity details the National Community Pharmacists Association's (NCPA's) next pharmacy benefit manager (PBM) reform priorities, focusing on fair pharmacy reimbursement and congressional scrutiny of health care consolidation and vertical integration.

Derek Webb and Dennis Williams outline practical, patient-centered strategies pharmacists can use to personalize OTC allergy recommendations, explain nondrowsy antihistamines clearly, and deliver efficient counseling in busy community settings.

Pitolisant is now the first and only FDA-approved nonscheduled treatment for cataplexy in pediatric and adult patients with narcolepsy.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Anne Cassity explains how Medicare Part D’s move to flat PBM service fees in 2028 may reduce incentives for high-cost formulary placement and support more cost-conscious medication decisions.

Niels Lund, expert investigator, reveals how early type 2 diabetes care slashes greenhouse gas emissions, boosts life years, and curbs costly complications.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.

Anne Cassity of the NCPA outlines the historic passage of federal pharmacy benefit manager (PBM) reform and explains how new Medicare Part D contracting standards could reshape reimbursement and oversight for community pharmacies.

Derek Webb and Dennis Williams discuss key global learnings from the FIP World Congress of Pharmacy, highlighting how pharmacists worldwide are leading proactive OTC allergy care and what practical strategies US community pharmacies can adopt.

Pharmacists are central to optimizing chronic kidney disease (CKD) diagnosis and monitoring long-term adherence to disease-modifying therapies.

Ann Marie Navar, MD, PhD, explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.

Sarah Nelson, PharmD, explains how pharmacists can simplify cardiovascular treatment regimens through personalized education, shared decision-making, and cross-sector collaboration to improve adherence and close care gaps in heart disease prevention.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.

Incremental, plant-based dietary changes can improve glycemic control, weight, and lipid outcomes while complementing cardiometabolic pharmacotherapy in routine pharmacy practice.

The platform offers uninsured patients discounted drug prices, though it is important to note that the platform does not sell drugs, and only a small number are currently available.

The scientific statement underscores obesity as a complex, socially driven condition and positions pharmacists as key partners in reducing stigma, improving access to care, and supporting equitable weight management.

Sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) were found to reduce the risk of chronic kidney disease (CKD) and key associated factors, like eGFR and albuminuria.